Loading the section…

CTNM: financial statements from SEC — TradeAlmanac

CTNM

Contineum Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	—	—	—	—	0	0
Research and development	12M	11M	14M	14M	10M	8M
Selling, general and administrative	5M	4M	4M	4M	3M	3M
Operating expenses	17M	15M	18M	18M	13M	11M
Operating income	−17M	−15M	−18M	−18M	−13M	−11M
Pre-tax income	—	—	—	—	−10M	−9M
Income tax	—	—	—	—	0	0
Net income	−14M	−13M	−16M	−16M	−10M	−9M
Earnings per share	−0.39	−0.45	−0.62	−0.62	−0.40	−0.39
Earnings per share, diluted	−0.39	—	—	−0.62	−0.40	−0.39
Weighted average shares	37M	28M	26M	26M	26M	23M
Weighted average shares, diluted	37M	—	—	26M	26M	23M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	20M	76M	43M	21M	22M	22M	41M	77M
Short-term investments	226M	187M	140M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−16M	−14M
Depreciation and amortisation	83,000	78,000
Share-based compensation	4M	3M
Capital expenditure	312,000	47,000
Investing cash flow	−39M	15M
Financing cash flow	129,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator